Amylyx Pharmaceuticals, Inc. (AMLX)
$27.03+0.67%Close
SELLCRISIS · day 2
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $3.0B
- Beta
- -0.20
- P/E (TTM)
- -19.17
- Short % float
- 15.38%
- Days to cover
- 9.2
- SI change
- -6.3%
- 1W
- -1.46%
- 1M
- -18.46%
- vs SPY 1W
- -1.32%
- vs SPY 1M
- -20.97%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 19
- VALUE
- 8
- GROWTH
- 47
- GARP
- 6
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-31.8%
REV YoY-
ROE-52.9%
EPS YoY-
ROA-57.5%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-19.17
P/E FWD-
SECTOR PE20.48
INDUSTRY PE13.99
P/B12.57
P/FCF-
EV/EBITDA-19.77
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E2.20
ALTMAN Z-
CURR RATIO12.12
ND/EBITDA-
BETA-0.20
Company news
FAQ
- What is LOPJLB’s current signal on AMLX?
- LOPJLB’s latest quantitative signal on Amylyx Pharmaceuticals, Inc. (AMLX) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is AMLX in?
- Amylyx Pharmaceuticals, Inc. (AMLX) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Amylyx Pharmaceuticals, Inc. (AMLX) do?
- Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under inve…